Better compliance with good manufacturing practice (GMP) has resulted from the efforts by the European Fine Chemicals Group (EFCG), according to Hovione’s chief executive officer Guy Villax. But the group is still worried about the quality of active pharmaceutical ingredients (APIs) made outside Europe for European consumption, he says, and a greater deterrent effect is still needed to maintain progress.

Speaking to Generics bulletin, Villax says he is convinced that APIs...